For research use only. Not for therapeutic Use.
Acalabrutinib-d4 (CAS: 2699608-18-7), a premium pharmaceutical research compound designed for advanced oncology studies. As a deuterated analog of Acalabrutinib, it offers enhanced stability and improved pharmacokinetic properties. Acalabrutinib-d4 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies for B-cell malignancies, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Trusted by leading laboratories, Acalabrutinib-d4 is your go-to solution for cutting-edge cancer research. Unlock new possibilities in B-cell malignancy treatment with Acalabrutinib-d4, where innovation meets reliability.
| Catalog Number | S000110 |
| CAS Number | 2699608-18-7 |
| Molecular Formula | C26H19D4N7O2 |
| Purity | ≥95% |
| Target | Btk |
| IUPAC Name | 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-(3,4,5,6-tetradeuteriopyridin-2-yl)benzamide |
| InChI | InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1/i3D,4D,8D,13D |
| InChIKey | WDENQIQQYWYTPO-FJSIYNKGSA-N |
| SMILES | [2H]C1=C(C(=NC(=C1[2H])NC(=O)C2=CC=C(C=C2)C3=C4C(=NC=CN4C(=N3)[C@@H]5CCCN5C(=O)C#CC)N)[2H])[2H] |
| Reference | [1]. Wu J, et al. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016 Mar 9;9:21 |
